Peptide YY(1-36) and peptide YY(3-36) are involved in appetite suppression after weight loss

	Tweet

Peptide YY(1-36) and peptide YY(3-36) are involved in appetite suppression after weight loss.

According to a recent review from the United States, “Peptide YY (PYY) is secreted as a 36 amino acid, straight chain polypeptide, and is found in greatest concentrations in the terminal ileum, colon and rectum. After secretion, dipeptidyl peptidase IV (DPP-IV) cleaves the N-terminal Tyrosine-Proline residues from PYY(1-36), producing PYY(3-36).”

G.H. Ballantyne at Hackensack University found, “PYY(1-36) acts at all four human Y receptors, Y1,Y2, Y4 and Y5, while PYY(336) is a specific Y2 receptor agonist. PYY participates in the regulation of appetite and weight balance through hypothalamic-based mechanisms. PYY(1-36) stimulates appetite and weight gain through Y1 and Y5 receptors.

PYY(3-36) suppresses appetite and stimulates weight loss through Y2 receptors, GI diseases that cause malabsorption increase both basal and meal-stimulated PYY levels.”

“In contrast,” the author continued, “obesity decreases both basal and mealstimulated PYY levels. Mutations in the human PYY and Y2 receptor genes may contribute to the development of obesity. Small bowel resection elevates PYY levels in humans. Colon resections increase PYY levels in animal models but not in man. PYY changes following bariatric operations are incompletely studied.

“Vertical banded gastroplasty, open Roux-en-Y gastric bypass and jejuno-ileal bypass significantly elevate basal and meal-stimulated PYY levels. In dogs with Pavlov pouches, Roux-en-Y duodenojejunostomy (duodenal switch) increases PYY levels compared to Roux-en-Y gastrojejunostomy. DPP-IV activity is increased in obese individuals and remains increased after biliopancreatic diversion. Thus, diseases or operations which cause malabsorption, elevate basal and meal-stimulated PYY levels. Bariatric operations also increase basal and meal-stimulated PYY levels.”

The researchers finished, “This suggests that the combination of increased PYY levels and elevated levels of DPP-IV observed after bariatric operations may generate increased circulating levels of PYY(3-36), leading to hypothalamic-mediated suppression of appetite and promotion of weight loss through Y2 receptor mediated mechanisms..”

Ballantyne published the review of their research in Obesity Surgery (Peptide YY(1- 36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg, 2006;16(6):795-803).

For additional information, contact G.H. Ballantyne, Hackensack University, Medical Center, 20 Prospect Avenue, Suite 901, Hackensack, NJ 07601, USA.

The publisher of the journal Obesity Surgery can be contacted at: F DCommunications Inc., 3100 Bayview Avenue, Unit 4, Toronto, Ontario M2N 5L3, Canada.

RELATED STORIES:
Weight in pregnancy best controlled by diet, study shows   FDA advisers recommend approving weight loss drug   Bridal Hunger Games   Exercise, Group Support Work for Weight Loss   Misperception of weight is an important barrier to weight loss   Obesity drugs need heart studies, U.S. advisers say   Weight Loss Surgery and Diabetes: Expert Interview Opportunity   New evidence on effects of green coffee beans in weight loss   Chocolate lovers tend to weigh less: study   Weight loss won’t necessarily help teen girls’ self-esteem   How to Best Help Your Child Lose Weight: Lose Weight Yourself   Qnexa: Is the new anti-obesity drug too risky?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]